VIR:NASDAQVir Biotechnology, Inc. Analysis
Data as of 2026-09-10 - not real-time
$10.81
Latest Price
9/10Risk
Risk Level: High
Executive Summary
At $10.81, Vir Biotechnology, Inc. shows a bullish moving-average alignment, with shorter averages sitting above longer ones. The last 30 days have gained 22.1%. Relative strength is 56.8 — neutral — and the MACD signal is bullish. Recent trading has carved out support near $8.80 and resistance around $11.94.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Analyst price targets sit 92.2% above the current price. Revenue is growing at 19582.5% on a -83.0% profit margin.
Risk comes out at 9 of a possible 10, a high reading. With 30-day volatility of 49.6%, a beta of 1.74 and a maximum drawdown of 25.6%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 92 on the fear-greed composite.
The horizons diverge: buy near-term but hold on a long view, at 1/10 conviction over the longer horizon.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Analyst price targets sit 92.2% above the current price. Revenue is growing at 19582.5% on a -83.0% profit margin.
Risk comes out at 9 of a possible 10, a high reading. With 30-day volatility of 49.6%, a beta of 1.74 and a maximum drawdown of 25.6%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 92 on the fear-greed composite.
The horizons diverge: buy near-term but hold on a long view, at 1/10 conviction over the longer horizon.
Top Market Events
SAN FRANCISCO-- BUSINESS WIRE --Jul 22, 2026--Vir Biotechnology: Astellas Deal Pushes Cash Above $1 Billion And Extends Runway Into Second Half Of 2028 Vir...Updated Aug 5, 2026 0 SAN FRANCISCO-- BUSINESS WIRE --Aug 5, 2026-- Vir Biotechnology, Inc.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 4/10
Key Factors
- Short-term moving averages stacked above long-term ones
- Trading above the 200-day average of 8.64
- MACD momentum is positive
Medium Term
1–3 yearsNeutral
Model confidence: 3/10
Key Factors
- Short-term moving averages stacked above long-term ones
- Trading above the 200-day average of 8.64
- Analyst targets imply +92.2% versus the current price
Long Term
> 3 yearsNeutral
Model confidence: 1/10
Key Factors
- Negative profit margin of -83.0%
- Analyst targets imply +92.2% versus the current price
- Negative return on equity of -26.1%
Key Metrics & Analysis
Financial Health
Revenue Growth19582.50%
Profit Margin-83.00%
P/E Ratio-4.3
ROE-26.08%
ROA-14.51%
Debt/Equity9.49
P/B Ratio2.1
Op. Cash Flow$-202506000
Free Cash Flow$-38885876
Industry P/E29.8
Technical Analysis
TrendBullish
RSI56.8
Support$8.80
Resistance$11.94
MA 20$10.38
MA 50$9.77
MA 200$8.64
MACDBullish
VolumeIncreasing
Fear & Greed Index91.64
Valuation
Target Price$20.78
Upside/Downside92.21%
GradeFair
TypeGrowth
Risk Assessment
Beta1.74
Volatility49.62%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.